NCT01727076 - Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 15, 2013

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck CarcinomaRecurrent Non-Small Cell Lung CarcinomaRecurrent Renal Cell CarcinomaRecurrent Skin CarcinomaStage III Renal Cell CancerStage IIIA Cutaneous Melanoma AJCC v7Stage IIIA Non-Small Cell Lung Cancer AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIB Non-Small Cell Lung Cancer AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7Stage IV Non-Small Cell Lung Cancer AJCC v7Stage IV Renal Cell Cancer

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

BIOLOGICAL

Recombinant Human Interleukin-15

Given SC

Trial Locations (5)

20892

National Institutes of Health Clinical Center, Bethesda

53792

University of Wisconsin Hospital and Clinics, Madison

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

94304

Stanford Cancer Institute Palo Alto, Palo Alto

98109

Seattle Cancer Care Alliance, Seattle

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH